证券代码：000813 证券简称：德展健康 公告编号：2025-025 德展大健康股份有限公司 关于公司 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2025 年 4 月 27 日，德展大健康股份有限公司（以下简称"公司"）召开第 八届董事会第三十一次会议，会议以 9 票同意，0 票反对，0 票弃权，审议通过 了《关于公司 2024 年度利润分配预案的议案》，该议案尚需提交公司 2024 年年 度股东大会审议。现将具体情况公告如下： 一、2024 年度利润分配预案基本情况 根据中兴财光华会计师事务所（特殊普通合伙）出具的 2024 年度审计报告， 2024 年度公司合并口径期初未分配利润为 3,933,981,143.16 元，本期合并口径 实现归属于母公司股东的净利润为-20,413,065.61 元，截至 2024 年末公司合并 口径未分配利润为 3,913,568,180.55 元。2024 年母公司期初未分配利润为- 357,451,735.26 元，母公司本期实现净利润为-83,630,608.28 元，提取法定 ...

前十大流通股东累计持有： 121645.01万股，累计占流通股比： 56.2%，较上期变化： -9701.57万 股。 | 名称 持有数量(万股) | | 占总股本比例(%) | 增减情况(万股) | | --- | --- | --- | --- | | 上海岳野股权投资管理合伙企业(有限合伙) | 41413.81 | 19.13 | 不变 | | 新疆凯迪投资有限责任公司 | 40974.84 | 18.93 | 不变 | | 美林控股集团有限公司 | 20740.25 | 9.58 | -8632.77 | | 新疆凯迪矿业投资股份有限公司 | 10403.94 | 4.81 | 不变 | | 新疆金融投资(集团)有限责任公司 | 2280.19 | 1.05 | 不变 | | 曹乐生 | 1509.85 | 0.70 | -312.08 | | 香港中央结算有限公司 | 1366.29 | 0.63 | -467.68 | | 宋湘沙 | 1147.77 | 0.53 | -177.40 | | 王赫 | 907.50 | 0.42 | 新进 | | 南方中证1000ETF | 900.57 | 0 ...

按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求， 我们审计了德展大健康股份有限公司（以下简称"德展健康"）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 德展大健康股份有限公司 中兴财光华审专字（2025）第 226018 号 内部控制审计报告 中兴财光华审专字(2025)第226018号 德展大健康股份有限公司全体股东： 按照《企业内部控制基本规范》《企业内部控制应用指引》《企业内部控 制评价指引》的规定，建立健全和有效实施内部控制，并评价其有效性是德展 健康董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的有效性发 表审计意见，并对注意到的非财务报告内部控制的重大缺陷进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，德展健康于2024年12月31日按照《企业内部控制基本规范》和 相 ...

德展大健康股份有限公司 中兴财光华审会字（2025）第 226019 号 目录 | 审计报告 | 1-5 | | --- | --- | | 合并及公司资产负债表 | 6-8 | | 合并及公司利润表 | 9-10 | | 合并及公司现金流量表 | 11-12 | | 合并及公司股东权益变动表 | 13-20 | | 财务报表附注 | 21-105 | 审计报告 中兴财光华审会字(2025)第 226019 号 德展大健康股份有限公司全体股东： 一、审计意见 我们审计了德展大健康股份有限公司（以下简称德展健康）财务报表，包 括 2024年 12 月 31 日的合并及公司资产负债表，2024 年度的合并及公司利润表、 合并及公司现金流量表、合并及公司股东权益变动表以及财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的规定编制， 公允反映了德展健康 2024 年 12 月 31 日的合并及公司财务状况以及 2024 年度的 合并及公司经营成果和现金流量。 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的 "注册会计师对财务报表审计的责任"部分进一步阐述了 ...

Corporate Governance and Compliance - The company reported a plan not to distribute cash dividends, issue bonus shares, or increase capital from reserves[5] - The company has a structured governance framework with a clear division of responsibilities among the shareholders' meeting, board of directors, supervisory board, and management[140] - The company is committed to maintaining compliance with laws and regulations regarding corporate governance and operations[141] - The company emphasizes the importance of protecting the rights of all shareholders, particularly minority shareholders, in its governance practices[139] - The company has established a market value management system to enhance its market value management practices[136] - The company has not reported any competitive conflicts with its controlling shareholder[144] - The company has a clear strategy for maintaining independence in business operations, personnel, assets, and finances[142] - The company has not implemented any employee stock ownership plans or other employee incentive measures during the reporting period[180] - The company has committed to ongoing monitoring and evaluation of risk control measures to ensure their effectiveness and compliance with established policies[183] - The company has conducted various research and communication activities with institutional investors to discuss operational conditions and R&D progress[134] Financial Performance - The company's operating revenue for 2024 was ¥466,485,016.50, a decrease of 6.34% compared to ¥498,088,171.28 in 2023[19] - The net profit attributable to shareholders for 2024 was -¥20,413,065.61, representing a decline of 124.50% from ¥83,314,246.81 in 2023[20] - The cash flow from operating activities for 2024 was -¥14,589,208.64, a significant drop of 111.41% compared to ¥127,872,780.78 in 2023[20] - The basic earnings per share for 2024 was -¥0.0095, down 124.87% from ¥0.0382 in 2023[20] - Total assets at the end of 2024 were ¥5,319,833,620.49, a decrease of 1.09% from ¥5,378,612,557.62 at the end of 2023[20] - The net assets attributable to shareholders at the end of 2024 were ¥5,158,023,472.59, down 1.53% from ¥5,237,902,679.94 at the end of 2023[20] - The company reported a negative net profit for the most recent accounting year, indicating uncertainty about its ability to continue as a going concern[21] - The company reported a net profit of -20,413,065.61 CNY for the fiscal year 2024, with an initial undistributed profit of 3,933,981,143.16 CNY[178] Research and Development - The company has a dedicated R&D platform with approximately 200 high-educated professionals, accounting for 20% of total employees, focusing on both technical improvements and new drug development[61] - R&D investment for 2024 reached CNY 78,203.1 million, a year-on-year increase of 53.05%, accounting for 16.76% of operating revenue, up 6.50 percentage points from the previous year[69] - The company is investing heavily in R&D, with a budget allocation of 200 million yuan for new technology development[161] - The company has completed three pharmacodynamic studies and two mechanism studies for the CBD project aimed at treating pulmonary hypertension[88] - The company is developing a new drug for pancreatic cancer, having secured multiple patent rights across various countries[89] - The company is on track to launch a collagen product for post-surgical recovery by 2024, with ongoing trials for other cosmetic peptides[89] Market and Sales Performance - The total market size for lipid-regulating agents in China exceeded 20 billion yuan in 2023, with a year-on-year growth of 0.10%[30] - The retail market for oral lipid-regulating agents in China grew by 12.37% year-on-year in the first three quarters of 2024, with total sales exceeding 5 billion yuan[35] - The sales of atorvastatin calcium tablets reached 6.07 billion yuan in 2023, maintaining its position as the top product in the cardiovascular drug market[38] - The company is actively enhancing its OTC market presence and collaborating with strategic partners to promote "Alo" in retail markets[55] - The company is expanding its product matrix and exploring new market opportunities to drive growth and enhance its competitive position[56] Environmental Compliance - The company is compliant with multiple environmental protection laws and regulations, including the Environmental Protection Law and the Solid Waste Pollution Prevention Law[190] - The company holds a valid pollution discharge permit effective from June 12, 2024, to June 11, 2029[191] - The company has established emergency response plans for environmental incidents, with documentation filed with local authorities[192] - The company reported emissions of nitrogen oxides at 2 units with a concentration of 80 mg/Nm3, complying with the standard of 100 mg/Nm3[193] - The company has successfully completed environmental protection acceptance for its construction projects[192] Strategic Initiatives - The company is actively exploring new business areas, including biopolypeptides and medical services, with some segments already producing end products[43] - The company aims to reshape its competitiveness through a technology innovation strategy, focusing on biopharmaceuticals and expanding into the health industry[65] - The company plans to enhance shareholder returns through a three-year shareholder return plan (2023-2025) to balance interests between the company and its shareholders[177] - The company plans to use between 200 million and 300 million RMB of its own funds for share repurchases to enhance investor returns, with ongoing repurchase activities expected in 2025 based on market conditions[179] Risk Management - The company has identified and quantified risks in financial, investment, and compliance areas, establishing a comprehensive risk prevention mechanism to support stable development[182] - The company faces risks from market and policy changes, particularly due to the ongoing reforms in drug procurement and stricter regulations[132] - Rising production costs due to raw material prices and logistics are a concern, prompting the company to optimize supplier management and production technology[132] Employee Management - The total number of employees at the end of the reporting period was 1,054, with 435 in production, 179 in sales, and 202 in technical roles[171][172] - The company has established a three-dimensional dynamic compensation system focused on value creation and performance-driven principles[173] - The training plan for 2024 includes 24 different training programs, covering areas such as GMP regulations, financial management, and quality management systems[174][175]

Financial Performance - The company's operating revenue for Q1 2025 was ¥89,277,784.01, a decrease of 11.82% compared to ¥101,250,441.65 in the same period last year[5]. - The net loss attributable to shareholders for Q1 2025 was ¥22,114,871.36, representing a 31.60% increase in loss from ¥16,805,072.84 in the previous year[5]. - The basic and diluted earnings per share for Q1 2025 were both -¥0.0104, a decline of 33.33% from -¥0.0078 in the same period last year[5]. - The net loss for the company was ¥29,276,212.82, which is a 35.45% increase from a loss of ¥21,613,891.55 in the same period last year, attributed to decreased interest income and increased credit impairment losses[10]. - Operating profit for the current period was -¥25,695,994.02, compared to -¥16,623,167.08 in the previous period, indicating a worsening of 54.5%[28]. - Net profit for the current period was -¥29,276,212.82, compared to -¥21,613,891.55 in the previous period, representing an increase in losses of 35.5%[28]. Cash Flow and Assets - The net cash flow from operating activities decreased by 20.60% to ¥18,042,709.30 from ¥22,723,297.27 year-on-year[5]. - The net cash flow from investing activities decreased by 82.21% to -¥37,670,373.09, compared to -¥20,673,911.95 in the previous year, mainly due to increased cash payments for fixed assets and intangible assets[10]. - The company’s cash and cash equivalents increased to 2,565,530,124.91 CNY from 2,530,699,274.17 CNY, reflecting a growth of approximately 1.4%[21]. - Cash flow from operating activities generated a net cash inflow of ¥18,042,709.30, down from ¥22,723,297.27 in the previous period, a decrease of 20.5%[31]. - Cash and cash equivalents at the end of the period totaled ¥2,480,454,564.29, a slight decrease from ¥2,731,014,590.64 in the previous period[33]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 65,376[13]. - The largest shareholder, Shanghai Yueye Equity Investment Management Partnership, holds 19.13% of shares, totaling 414,138,066 shares, with 25,250,000 shares frozen[13]. - The second largest shareholder, Xinjiang Kaidi Investment Co., Ltd., holds 18.93% of shares, totaling 409,748,445 shares, with 143,000,000 shares pledged[13]. - The top three shareholders collectively hold over 47% of the company's shares[13]. - The company has a repurchase account holding 28,567,500 shares, representing 1.32% of total shares[15]. - The company is conducting multiple rounds of public auctions for shares held by major shareholders, with recent auctions resulting in the successful sale of 25,250,000 shares[16]. - The report indicates that there are no changes in the top 10 shareholders due to securities lending or borrowing activities[16]. - The company has not issued any preferred shares or disclosed any preferred shareholders[16]. Assets and Liabilities - Total assets at the end of Q1 2025 were ¥5,355,877,868.80, an increase of 0.68% from ¥5,319,833,620.49 at the end of the previous year[5]. - The company’s total liabilities increased to 220,204,515.49 CNY from 154,884,054.36 CNY, representing a significant rise of approximately 42%[23]. - The company’s long-term borrowings amounted to 40,000,000.00 CNY, which was previously zero, indicating new financing activities[23]. - The company’s inventory increased to 209,630,292.48 CNY from 197,873,887.61 CNY, showing a growth of about 5.4%[22]. - The company’s accounts receivable decreased to 217,755,087.09 CNY from 242,227,524.74 CNY, reflecting a decline of approximately 10.1%[21]. Research and Development - The company signed a strategic cooperation framework agreement with Baoshihua Pharmaceutical Technology (Beijing) Co., Ltd. to enhance its health service system[19]. - The company’s subsidiary received approval for a clinical trial for a new drug targeting HPV-related conditions, showcasing ongoing R&D efforts[19]. - Research and development expenses for the current period were ¥10,024,839.12, down from ¥10,877,646.84 in the previous period, a decrease of 7.8%[28]. Other Income and Expenses - The company reported a significant increase of 96.91% in other income to ¥2,066,921.45, primarily due to increased government subsidies[10]. - Investment losses for Q1 2025 were ¥3,976,605.05, a 124.02% increase compared to losses of ¥1,775,111.21 in the previous year, mainly due to a decline in net profits from joint ventures[10]. - Total operating costs decreased to ¥99,442,024.53 from ¥106,513,804.78, reflecting a reduction of 6.3%[27].

Core Viewpoint - The announcement from 德展大健康股份有限公司 details the completion of share transfers involving significant shareholders, 上海岳野 and 美林控股, without affecting the company's control or operations [1][2][3]. Share Transfer Summary - 上海岳野 completed the auction transfer of 25,250,000 shares, representing 1.17% of the total share capital, reducing its holding from 19.13% to 17.96% [2]. - The shares were auctioned on the 京东 judicial auction platform, and the transfer was completed in compliance with legal regulations [2]. - The new shareholder is restricted from selling the acquired shares within six months [2]. Forced Reduction Summary - 美林控股 underwent a forced reduction of 15,127,500 shares due to a default in a stock pledge repurchase agreement, with a total of 21,363,800 shares executed, accounting for 0.99% of the total share capital [3]. - The forced execution price ranged from 3.15 to 3.48 yuan per share [3]. - 美林控股 is not a controlling shareholder, and this reduction will not impact the company's governance or operations [3]. Commitments and Compliance - 上海岳野 is fulfilling its commitment to reduce and regulate related party transactions without any violations [3]. - 美林控股 is also adhering to its commitments, although there is a dispute regarding performance commitments with 新疆凯迪投资, which has led to an arbitration application [3].

证券代码：000813 证券简称：德展健康 公告编号：2025-021 德展大健康股份有限公司 关于持股 5%以上股东股份拍卖过户完成及 被动减持完成的公告 股东美林控股集团有限公司、上海岳野股权投资管理合伙企业（有限合伙） 保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 德展大健康股份有限公司（以下简称"公司"）于近日收到公司持股 5%以 上股东上海岳野股权投资管理合伙企业（有限合伙）清算组（以下简称"上海岳 野"）出具的《股票拍卖过户告知函》，获悉其在第三次拍卖股份中被竞拍成功 的公司 25,250,000 股股份已于近日完成过户登记手续，上述股份占公司目前总 股本比例为 1.17%，占剔除公司回购专用账户股份数量后的公司总股本比例为 1.18%1。同时，根据公司持股 5%以上股东美林控股集团有限公司（以下简称"美 林控股"）发来的《关于司法强制执行完成的告知函》，其前期拟被司法强制执 行的股份已被执行完毕。此次共计被执行股份 21,363,800 股，占公司总股本的 比例为 0.99%，占剔除公司回购 ...

证券代码：000813 证券简称：德展健康 公告编号：2025-022 德展大健康股份有限公司 德展大健康股份有限公司（以下简称"公司"）持股 5%以上股东上海岳野股 权投资管理合伙企业（有限合伙）（以下简称"上海岳野"）第三次拍卖股份中 被竞拍成功的公司 25,250,000 股股份已于近日完成过户登记手续，其所持公司 股 份 变 动 超 过 1% ， 具 体 情 况 请 详 见 公 司 于 同 日 在 巨 潮 资 讯 网 （www.cninfo.com.cn）等指定信息披露媒体披露的《关于持股 5%以上股东减持 股份的公告》（公告编号：2025-021）。根据相关规定，现将有关情况公告如下： | 1．基本情况 | | | | | --- | --- | --- | --- | | 信息披露 | 上海岳野股权投资管理合伙企业（有限合伙） | | | | 义务人 | | | | | 住所 | 北京市朝阳区嘉泰国际大厦 | A 座 1705 | | | 权益变动 | 2025 年 4 月 | | | | 时间 | | | | | 股票简称 | 股票 德展健康 | | 000813 | | | 代码 | | | ...

德展大健康股份有限公司（以下简称"公司"）原定于 2025 年 4 月 25 日披 露《2024 年年度报告》《2025 年第一季度报告》。因公司年报编制及复核工作 仍在开展中，为保证公司定期报告信息披露内容的真实、准确和完整，本着审慎 原则及对广大投资者负责的态度，经向深圳证券交易所申请，公司将《2024 年年 度报告》及《2025 年第一季度报告》披露时间调整至 2025 年 4 月 29 日。 公司董事会对本次调整定期报告披露时间给广大投资者带来的不便致以诚 挚的歉意，敬请广大投资者谅解。公司指定信息披露媒体为《证券时报》《证券 日报》《上海证券报》《中国证券报》及巨潮资讯网(www.cninfo.com.cn)，公 司所有信息均以在上述指定媒体披露的信息为准，敬请广大投资者关注公司公告 并注意投资风险。 特此公告。 德展大健康股份有限公司董事会 证券代码：000813 证券简称：德展健康 公告编号：2025-020 德展大健康股份有限公司 关于延期披露 2024 年年度报告及 2025 年第一季度报告的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏 ...